BCDA
Price
$1.43
Change
+$0.02 (+1.42%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
14.96M
NBY
Price
$2.18
Change
+$0.04 (+1.87%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
12.85M
Interact to see
Advertisement

BCDA vs NBY

Header iconBCDA vs NBY Comparison
Open Charts BCDA vs NBYBanner chart's image
BioCardia
Price$1.43
Change+$0.02 (+1.42%)
Volume$4.39K
Capitalization14.96M
NovaBay Pharmaceuticals
Price$2.18
Change+$0.04 (+1.87%)
Volume$297
Capitalization12.85M
BCDA vs NBY Comparison Chart in %
Loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCDA vs. NBY commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a Buy and NBY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (BCDA: $1.43 vs. NBY: $2.18)
Brand notoriety: BCDA and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 14% vs. NBY: 1%
Market capitalization -- BCDA: $14.96M vs. NBY: $12.85M
BCDA [@Biotechnology] is valued at $14.96M. NBY’s [@Biotechnology] market capitalization is $12.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 3 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 3 green, 2 red.
According to our system of comparison, NBY is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 5 TA indicator(s) are bullish while NBY’s TA Score has 5 bullish TA indicator(s).

  • BCDA’s TA Score: 5 bullish, 5 bearish.
  • NBY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both BCDA and NBY are a good buy in the short-term.

Price Growth

BCDA (@Biotechnology) experienced а +23.28% price change this week, while NBY (@Biotechnology) price change was +19.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCDA($15M) has a higher market cap than NBY($12.9M). NBY YTD gains are higher at: 262.729 vs. BCDA (-35.321). NBY has higher annual earnings (EBITDA): -7.05M vs. BCDA (-8.81M). NBY has more cash in the bank: 5.34M vs. BCDA (980K). BCDA has less debt than NBY: BCDA (745K) vs NBY (1.04M). NBY has higher revenues than BCDA: NBY (9.78M) vs BCDA (0).
BCDANBYBCDA / NBY
Capitalization15M12.9M116%
EBITDA-8.81M-7.05M125%
Gain YTD-35.321262.729-13%
P/E RatioN/A0.93-
Revenue09.78M-
Total Cash980K5.34M18%
Total Debt745K1.04M71%
FUNDAMENTALS RATINGS
BCDA vs NBY: Fundamental Ratings
BCDA
NBY
OUTLOOK RATING
1..100
5087
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
9434
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for BCDA (88) in the null industry. This means that NBY’s stock grew somewhat faster than BCDA’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that NBY’s stock grew similarly to BCDA’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for BCDA (100) in the null industry. This means that NBY’s stock grew significantly faster than BCDA’s over the last 12 months.

NBY's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for BCDA (94) in the null industry. This means that NBY’s stock grew somewhat faster than BCDA’s over the last 12 months.

NBY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for BCDA (100) in the null industry. This means that NBY’s stock grew significantly faster than BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDANBY
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IPGP79.280.04
+0.05%
IPG Photonics Corp
STM28.30-0.72
-2.48%
STMicroelectronics NV
ORKT0.61-0.02
-3.54%
Orangekloud Technology Inc
PROF5.12-0.25
-4.66%
Profound Medical Corp
IOVA2.02-0.10
-4.72%
Iovance Biotherapeutics

BCDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCDA has been closely correlated with RNAC. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if BCDA jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCDA
1D Price
Change %
BCDA100%
-4.73%
RNAC - BCDA
85%
Closely correlated
-6.06%
CDTX - BCDA
85%
Closely correlated
-4.31%
AGEN - BCDA
85%
Closely correlated
-8.67%
NBY - BCDA
84%
Closely correlated
-0.93%
TAOX - BCDA
84%
Closely correlated
-8.22%
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+1.87%
CDTX - NBY
93%
Closely correlated
+6.84%
NCNA - NBY
93%
Closely correlated
+0.75%
TAOX - NBY
91%
Closely correlated
+6.22%
RNAC - NBY
91%
Closely correlated
-2.43%
AGEN - NBY
90%
Closely correlated
+1.54%
More